Prana Biotechnology Ltd. (NASDAQ:PRAN) shares saw strong trading volume on Tuesday . 397,458 shares changed hands during mid-day trading, an increase of 66% from the previous session’s volume of 239,764 shares.The stock last traded at $5.66 and had previously closed at $5.80.

Separately, Zacks Investment Research raised Prana Biotechnology from a “sell” rating to a “hold” rating in a research note on Wednesday, August 3rd.

The stock’s market cap is $8.87 million. The firm has a 50-day moving average price of $4.70 and a 200 day moving average price of $3.82.

Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders. The Company’s lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.